Effective strategy of withdrawal of pharmacological treatment of urinary incontinence in children (StayDry)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510280-35-00

Acronym

StayDry-2023

Enrollment

216

Registered

2024-04-22

Start date

2024-05-27

Completion date

Unknown

Last updated

2024-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Daytime urinary incontinence

Brief summary

The primary outcome measure is recurrence of incontinence after withdrawal and up to 12 months follow-up, assessed by 14-day calendar of incontinence episodes.

Detailed description

Secondary outcome measures are development of any withdrawal symptoms, assessed by questionnaire on withdrawal symptoms (Appendix 2), change from baseline up to 44 days after initiation of withdrawal.

Interventions

DRUGSOLIFENACIN

DRUGMIRABEGRON

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is recurrence of incontinence after withdrawal and up to 12 months follow-up, assessed by 14-day calendar of incontinence episodes.	—

Secondary

Measure	Time frame
Secondary outcome measures are development of any withdrawal symptoms, assessed by questionnaire on withdrawal symptoms (Appendix 2), change from baseline up to 44 days after initiation of withdrawal.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026